NeuroTherapia, Inc, a Delaware C-corporation was founded in 2015 by the Cleveland Clinic and two of its physician scientists. The Company is developing new drugs to treat diseases related to neuroinflammation with an initial focus on Alzheimer’s disease (AD) therapies. The Company’s lead molecule, NTRX-07, is a cannabinoid type II receptor agonist.
Extensive research demonstrated the ability of NTRX-07 to reduce neuroinflammation and improve neuronal function, leading to improvements in learning and memory, without any of the psychoactive side effects associated with cannabinoids. The Company completed initial preclinical toxicology work in 2018, and recruited Tony Giordano, Ph.D., an experienced biotechnology CEO to run NeuroTherapia. The Company is currently completing Phase I clinical development, while also expanding its pipeline of potential indications and new therapies targeting neuroinflammation.